Table 7 Comparison between patients with elevated post-treatment METTL3 gene expression versus patients with lowered post-treatment gene levels regarding BM blast counts in follow-up samples
BM blast counts% | AML group with elevated normalized METTL3 gene expression post-treatment (n = 9) | AML group with reduced normalized METTL3 gene expression post-treatment (n = 6) | χ2 | p value | ||
|---|---|---|---|---|---|---|
No | % | No | % | |||
Assessment of maintenance of CR | ||||||
2nd month BM blast counts% | ||||||
≤ 5% | 4 | 44.4% | 6 | 100.0% | 3.905 | 0.048* |
> 5% | 5 | 55.6% | 0 | 0.0% | ||
4th month BM blast counts% | ||||||
≤ 5% | 2 | 22.2% | 6 | 100.0% | 5.904 | 0.015* |
> 5% | 7 | 77.8% | 0 | 0.0% | ||
6th month BM blast counts% | ||||||
≤ 5% | 2 | 22.2% | 6 | 100.0% | 5.904 | 0.015* |
> 5% | 7 | 77.8% | 0 | 0.0% | ||